@entity1153 treatment and potential biomarkers in @entity308 XXXX following an initial SSRI treatment failure: a prospective, open-label, 24-week study.

@entity1 @entity650 @entity308 @entity4237 @entity1153 @entity13468 @entity750 @entity687 @entity1063
BACKGROUND: We assessed the effect of switching @entity1 with major @entity308 to @entity1153 following an initial selective @entity750 reuptake inhibitor treatment failure, and explored potential biomarkers in their blood. METHODS: We conducted a prospective, open-label, 24-week trial. @entity308 was assessed with the 17-item Hamilton @entity308 Rating Scale. @entity1 showing a >= 50% reduction in Hamilton @entity308 Rating Scale scores from baseline to final visit were considered responders. Regarding @entity4237 ( @entity4237 ), moderate-to-severe @entity4237 were specifically identified as effects that required any medical treatment or that induced treatment withdrawals. We also measured blood levels of various molecules including inflammatory cytokines. RESULTS: Of the 30 @entity1 who enrolled, 17 completed this study. The responder rate was 30% (n=10). Baseline serum levels of @entity650 (Z=-2.155; P=0.031) and @entity687 (Z=-2.616; P=0.009) were significantly higher when moderate-to-severe @entity4237 were present (n=13 @entity1 with moderate-to-severe @entity4237 ). Serum levels of @entity13468 showed a significant continuous decrease from the baseline level (Friedman's test:    (2)=23.9, df=4, P<0.001) only in non-responders. CONCLUSION: These results demonstrate that serum levels of @entity650 , @entity687 , and @entity13468 as potential blood biomarkers could be utilized to identify the responsiveness of @entity1 to @entity750 and @entity1063 reuptake inhibitor like @entity1153 , or to identify those @entity1 who may experience @entity4237 strong enough to warrant discontinuation of treatment.
